COPD

 
Depression, Anxiety Underrecognized and Undertreated in COPD, Increasing Disease Burden
March 27, 2025

A new analysis reveals significant gaps in diagnosis of and treatment for psychiatric disorders in adults with COPD and calls for larger, longitudinal studies.

Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose
March 24, 2025

Your daily dose of the clinical news you may have missed.

Dupilumab Found Beneficial in COPD with Type 2 Inflammation: Daily Dose
March 20, 2025

Your daily dose of the clinical news you may have missed.

FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar
March 10, 2025

Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.

Dupilumab Shows Efficacy and Safety in COPD With Type 2 Inflammation: AAAAI 2025
March 06, 2025

Investigators concluded that dupilumab reduced exacerbation rates, improved lung function, and decreased systemic corticosteroid use in patients with COPD driven by type 2 inflammation.

Expert Perspectives 2024: Biologics for Management of COPD with MeiLan K Han, MD, MS
December 12, 2024

The GOLD report committee member highlights advances in knowledge of COPD phenotypes and the new role for biologic medications in this year's video series.

FDA Accepts GSK’s Submission for Use of Mepolizumab in COPD
December 09, 2024

The Prescription Drug User Fee Act date is set for May 7, 2025.

"Be Vigilant About Risk Factors for COPD, Aggressive with Questions About Symptoms," Expert Advises Primary Care
November 25, 2024

COPD expert MeiLan K Han, MD, MS, says that in the absence of a definitive single tool to assess for COPD, probing patients for risk factors and symptoms is essential.

2025 GOLD Report on COPD Addresses Cardiovascular Risk in New Section: MeiLan Han, MD, MS, Highlights Rationale
November 22, 2024

Cardiovascular comorbidities in adults with COPD are linked to poor outcomes including reduced QoL, increased hospitalizations, and greater risk of mortality, Han explains.